• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

    5/7/25 4:05:00 PM ET
    $KRMD
    Medical/Dental Instruments
    Health Care
    Get the next $KRMD alert in real time by email

    KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025.

    Recent Highlights

    • First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period
    • Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period
    • Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over the prior year period
    • Ending cash balance of $8.7 million and quarterly cash usage of $0.8 million
    • Announcing plans to submit for FDA 510(k) clearance for 2 commercialized drugs with the Freedom Infusion System™ in 2025
    • Raising full year 2025 revenue guidance to $38.5 – $39.5 million from prior range of $38.0 - $39.0 million; reiterating full year gross margin guidance of 61% - 63%, and positive cash flow from operations for full year 2025

    "We are off to a strong start this year, with over 20% growth in our core business driven by new patient starts and continued market share gains both domestically and internationally, all contributing to the expansion of our recurring revenue base," said Linda Tharby, President and CEO of KORU Medical. "We are also advancing our novel therapies pipeline and announcing plans to submit two previously commercialized drugs for 510(k) clearance with the Freedom Infusion system by year-end. Despite a challenging macroeconomic backdrop, the positive momentum in our business gives us confidence in our ability to deliver through the remainder of the year, and we are raising our full-year revenue guidance accordingly."

    2025 First Quarter Financial Results

     

     

     

    Three Months Ended March 31,

     

    Change from Prior Year

    % of Net Revenues

     

     

    2025

     

    2024

     

    $

    %

    2025

     

    2024

    Net Revenues

     

     

     

     

     

     

     

     

     

     

     

     

     

    Domestic Core

     

    $

    6,927,964

     

    $

    5,953,865

     

    $

    974,099

     

    16.4

    %

    71.9

    %

     

    72.6

    %

    International Core

     

     

    2,428,662

     

     

    1,790,483

     

     

    638,179

     

    35.6

    %

    25.2

    %

     

    21.8

    %

    Total Core

     

     

    9,356,626

     

     

    7,744,348

     

     

    1,612,278

     

    20.8

    %

    97.1

    %

     

    94.5

    %

    Pharma Services and Clinical Trials

     

     

    278,449

     

     

    453,450

     

     

    (175,001

    )

    (38.6

    %)

    2.9

    %

     

    5.5

    %

    Total

     

    $

    9,635,075

     

    $

    8,197,798

     

    $

    1,437,277

     

    17.5

    %

    100

    %

     

    100

    %

    Total net revenues increased $1.4 million, or 17.5%, to $9.6 million for the three months ended March 31, 2025, as compared to $8.2 million in the prior year period. Domestic core revenues were $6.9 million, an increase of 16.4% over the prior year period, primarily due to higher pump and consumable volumes, driven by new patient starts and market share gains within new and existing accounts, supported by a strong underlying SCIg market. International core revenues were $2.4 million, an increase of 35.6% over the prior year period, primarily due to higher pump and consumable volumes, driven by geographical expansion and a tender win with an Ig pharma partner. International growth was impacted by approximately $0.4 million of distributor stocking to support expansion, compared to $0.3 million of distributor stocking in the prior year as a result of the BSI regulatory review process. Pharma services and clinical trials net revenues were $0.3 million, a decrease of 38.6% over the prior year period, primarily due to lower clinical trial revenue.

    Gross profit increased $0.9 million, or 18.5%, to $6.0 million in the three months ended March 31, 2025, as compared to $5.1 million in the prior year period. Gross margin increased to 62.8% in the three months ended March 31, 2025, as compared to 62.3% in the prior year period. The increase in gross margin was primarily driven by favorable changes in product revenue mix.

    Total operating expenses for the first quarter of 2025 were $7.3 million, an increase of $0.2 million, or 3.2%, over the prior year period driven by increases in compensation-related expenses for temporary staff to support product development and legal fees, partially offset by lower severance and research and development expenses.

    Net loss decreased $0.8 million in the three months ended March 31, 2025, as compared to the prior year period, primarily driven by an increase in gross profit of $0.9 million, driven by increased revenues, partially offset by operating expense increases of $0.2 million.

    Adjusted EBITDA for the first quarter of 2025 was ($0.2) million, or ($0.00) per diluted share, compared to adjusted EBITDA of ($0.9) million, or ($0.02) per diluted share, for the for the prior year period. A reconciliation of adjusted EBITDA and adjusted diluted EPS is provided at the end of this press release.

    Cash and cash equivalents were $8.7 million as of March 31, 2025, reflecting cash usage of $0.8 million in the first quarter of 2025.

    2025 Guidance

    • Raising full year 2025 net revenues guidance to $38.5 - $39.5, representing growth of 15% - 17% from prior range of $38.0 - $39.0 million
    • Reiterating full year 2025 gross margin guidance of 61% - 63%
    • Reiterating positive cash flow from operations for full year 2025

    Conference Call and Webcast Details

    The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Wednesday, May 7, 2025, at 4:30 PM ET.

    To participate in the call, please dial (877) 407-0784 (domestic) or (201) 689-8560 (international). The live webcast will be available on the IR Calendar on the News/Events page of the Investors section of KORU Medical's website.

    Non-GAAP Measures

    This press release includes the non-GAAP financial measures "adjusted diluted EPS" and "adjusted EBITDA" that are not in accordance with, nor an alternate to, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. These non-GAAP measures are not based on any comprehensive set of accounting rules or principles. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on KORU Medical's reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company's financial results. Non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial results. Reconciliations of the Company's non-GAAP measures are included at the end of this press release.

    About KORU Medical Systems

    KORU Medical develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System ("the FREEDOM System") currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.

    Forward-looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements, including, but not limited to, timing of 510(k) clearances and financial guidance for fiscal 2025. Forward-looking statements discuss the Company's current expectations and projections relating to its financial position, results of operations, plans, objectives, future performance, and business. Forward-looking statements can be identified by words such as "guidance", "expect", "plan", "believe" and "will". Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, tariffs and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, which are on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of May 7, 2025. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

    KORU MEDICAL SYSTEMS, INC.

    BALANCE SHEETS

     

     

     

     

     

     

    March 31,

    December 31,

     

     

    2025

    2024

     

     

    (UNAUDITED)

     

     

     

     

     

     

     

    ASSETS

     

     

     

     

     

     

     

     

     

     

     

    CURRENT ASSETS

     

     

     

     

     

    Cash and cash equivalents

     

    $

    8,735,834

     

    $

    9,580,947

     

    Accounts receivable less allowance for credit losses of $0 as of March 31, 2025 and December 31, 2024

     

     

    5,949,411

     

     

    5,720,750

     

    Inventory

     

     

    3,278,646

     

     

    2,803,669

     

    Other receivables

     

     

    321,167

     

     

    277,193

     

    Prepaid expenses

     

     

    713,970

     

     

    749,851

     

    TOTAL CURRENT ASSETS

     

     

    18,999,028

     

     

    19,132,410

     

    Property and equipment, net

     

     

    4,533,949

     

     

    4,290,515

     

    Intangible assets, net of accumulated amortization of $475,891 and $458,538 as of March 31, 2025 and December 31, 2024, respectively

     

     

    716,326

     

     

    730,279

     

    Operating lease right-of-use assets

     

     

    2,867,894

     

     

    2,966,341

     

    Other assets

     

     

    98,970

     

     

    98,970

     

    TOTAL ASSETS

     

    $

    27,216,167

     

    $

    27,218,515

     

     

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

     

     

     

     

     

     

     

     

    CURRENT LIABILITIES

     

     

     

     

     

    Accounts payable

     

    $

    2,013,578

     

    $

    1,649,969

     

    Accrued expenses

     

     

    3,977,987

     

     

    3,924,184

     

    Note payable

     

     

    137,180

     

     

    271,152

     

    Other liabilities

     

     

    110,097

     

     

    29,269

     

    Accrued payroll and related taxes

     

     

    1,038,717

     

     

    811,401

     

    Financing lease liability – current

     

     

    117,105

     

     

    115,587

     

    Operating lease liability – current

     

     

    404,613

     

     

    400,258

     

    TOTAL CURRENT LIABILITIES

     

     

    7,799,277

     

     

    7,201,820

     

    Financing lease liability, net of current portion

     

     

    174,259

     

     

    202,613

     

    Operating lease liability, net of current portion

     

     

    2,897,600

     

     

    3,000,403

     

    TOTAL LIABILITIES

     

     

    10,871,136

     

     

    10,404,836

     

     

     

     

     

     

     

    STOCKHOLDERS' EQUITY

     

     

     

     

     

    Common stock, $0.01 par value, 75,000,000 shares authorized, 49,561,498 and 49,377,617 shares issued 46,140,996 and 45,957,115 shares outstanding as of March 31, 2025, and December 31, 2024, respectively

     

     

    495,615

     

     

    493,776

     

    Additional paid-in capital

     

     

    50,277,053

     

     

    49,581,303

     

    Treasury stock, 3,438,526 and 3,438,526 shares as of March 31, 2025 and December 31, 2024, respectively, at cost

     

     

    (3,882,494

    )

     

    (3,882,494

    )

    Accumulated deficit

     

     

    (30,545,143

    )

     

    (29,378,906

    )

    TOTAL STOCKHOLDERS' EQUITY

     

     

    16,345,031

     

     

    16,813,679

     

    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

     

    $

    27,216,167

     

    $

    27,218,515

     

    KORU MEDICAL SYSTEMS, INC.

    STATEMENTS OF OPERATIONS

    (UNAUDITED)

     

     

     

     

     

     

     

     

    Three Months Ended

     

     

    March 31,

     

     

    2025

    2024

     

     

     

     

     

     

    NET REVENUES

     

    $

    9,635,075

     

    $

    8,197,798

     

    Cost of goods sold

     

     

    3,588,740

     

     

    3,094,500

     

    Gross Profit

     

     

    6,046,335

     

     

    5,103,298

     

     

     

     

     

     

     

    OPERATING EXPENSES

     

     

     

     

     

    Selling, general and administrative

     

     

    5,959,374

     

     

    5,357,620

     

    Research and development

     

     

    1,114,609

     

     

    1,475,674

     

    Depreciation and amortization

     

     

    217,357

     

     

    231,370

     

    Total Operating Expenses

     

     

    7,291,340

     

     

    7,064,664

     

     

     

     

     

     

     

    Net Operating Loss

     

     

    (1,245,005

    )

     

    (1,961,366

    )

     

     

     

     

     

     

    Non-Operating Income/(Expense)

     

     

     

     

     

    Gain/(Loss) on currency exchange

     

     

    5,588

     

     

    (11,479

    )

    Loss on disposal of fixed assets, net

     

     

    —

     

     

    (300

    )

    Interest income, net

     

     

    73,180

     

     

    37,187

     

    TOTAL OTHER INCOME

     

     

    78,768

     

     

    25,408

     

     

     

     

     

     

     

    LOSS BEFORE INCOME TAXES

     

     

    (1,166,237

    )

     

    (1,935,958

    )

     

     

     

     

     

     

    Income Tax Benefit

     

     

    —

     

     

    —

     

     

     

     

     

     

     

    NET LOSS

     

    $

    (1,166,237

    )

    $

    (1,935,958

    )

     

     

     

     

     

     

    NET LOSS PER SHARE

     

     

     

     

     

     

     

     

     

     

     

    Basic & Diluted

     

    $

    (0.03

    )

    $

    (0.04

    )

     

     

     

     

     

     

    WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING

     

     

     

     

     

     

     

     

     

     

     

    Basic & Diluted

     

     

    45,981,826

     

     

    45,712,224

     

    KORU MEDICAL SYSTEMS, INC.

    STATEMENTS OF CASH FLOWS

    (UNAUDITED)

     

     

     

     

     

     

     

    For the

    Three Months Ended

     

     

    March 31,

     

     

    2025

    2024

     

     

     

     

     

     

    CASH FLOWS FROM OPERATING ACTIVITIES

     

     

     

     

     

    Net Loss

     

    $

    (1,166,237

    )

    $

    (1,935,958

    )

    Adjustments to reconcile net loss to net cash used in operating activities:

     

     

     

     

     

    Stock-based compensation expense and warrant expense

     

     

    697,590

     

     

    699,718

     

    Depreciation and amortization

     

     

    217,357

     

     

    231,370

     

    Loss on disposal of fixed assets

     

     

    —

     

     

    300

     

    Non-cash lease adjustments

     

     

    —

     

     

    (5,497

    )

    Changes in operating assets and liabilities:

     

     

     

     

     

    Accounts receivable

     

     

    (228,661

    )

     

    (607,125

    )

    Inventory

     

     

    (474,977

    )

     

    333,989

     

    Prepaid expenses and other assets

     

     

    (8,094

    )

     

    387,880

     

    Other liabilities

     

     

    80,828

     

     

    (54,867

    )

    Accounts payable

     

     

    363,608

     

     

    798,992

     

    Accrued payroll and related taxes

     

     

    227,316

     

     

    56,500

     

    Accrued expenses

     

     

    53,803

     

     

    (252,022

    )

    NET CASH USED IN OPERATING ACTIVITIES

     

     

    (237,467

    )

     

    (346,720

    )

     

     

     

     

     

     

    CASH FLOWS FROM INVESTING ACTIVITIES

     

     

     

     

     

    Purchases of property and equipment

     

     

    (443,438

    )

     

    (133,083

    )

    Purchases of intangible assets

     

     

    (3,400

    )

     

    (0

    )

    NET CASH USED IN INVESTING ACTIVITIES

     

     

    (446,838

    )

     

    (133,083

    )

     

     

     

     

     

     

    CASH FLOWS FROM FINANCING ACTIVITIES

     

     

     

     

     

    Payments on insurance finance indebtedness

     

     

    (133,973

    )

     

    (155,313

    )

    Payments on finance lease liability

     

     

    (26,835

    )

     

    (26,807

    )

    NET CASH USED IN FINANCING ACTIVITIES

     

     

    (160,808

    )

     

    (182,120

    )

     

     

     

     

     

     

    NET DECREASE IN CASH AND CASH EQUIVALENTS

     

     

    (845,113

    )

     

    (661,923

    )

    CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD

     

     

    9,580,947

     

     

    11,482,240

     

    CASH AND CASH EQUIVALENTS, END OF PERIOD

     

    $

    8,735,834

     

    $

    10,820,317

     

     

     

     

     

     

     

    Supplemental Information

     

     

     

     

     

    Cash paid during the periods for:

     

     

     

     

     

    Interest

     

    $

    5,385

     

    $

    12,296

     

    Income taxes

     

    $

    —

     

    $

    —

     

    KORU MEDICAL SYSTEMS, INC.

    SUPPLEMENTAL INFORMATION

    (UNAUDITED)

     

    A reconciliation of our non-GAAP measures is below:

     

     

     

    Three Months Ended

    Reconciliation of GAAP Net Loss

    March 31,

    to Non-GAAP Adjusted EBITDA:

    2025

    2024

    GAAP Net Loss

    $

    (1,166,237

    )

    $

    (1,935,958

    )

    Depreciation and Amortization

     

    217,357

     

     

    231,369

     

    Interest (Income), Net

     

    (73,180

    )

     

    (37,187

    )

    Reorganization Charges

     

    —

     

     

    99,329

     

    Litigation Expense

     

    133,411

     

     

     

    Stock-based Compensation Expense

     

    697,590

     

     

    699,718

     

    Adjusted EBITDA

    $

    (191,059

    )

    $

    (942,729

    )

     

    Weighted average number common shares

    45,981,826

    45,712,224

     

     

     

     

     

     

    Three Months Ended

    Reconciliation of Reported Diluted EPS

    March 31,

    to Non-GAAP Adjusted Diluted EPS:

    2025

    2024

    Reported Diluted Earnings Per Share

    $

    (0.03

    )

    $

    (0.04

    )

    Depreciation and Amortization

     

    —

     

     

    0.01

     

    Interest (Income)/Expense, Net

     

    —

     

     

    —

     

    Reorganization Charges

     

    —

     

     

    —

     

    Litigation Expense

     

    —

     

     

    —

     

    Stock-based Compensation Expense

     

    0.02

     

     

    0.02

     

    Adjusted Diluted Earnings Per Share

    $

    0.00

     

    $

    (0.02

    )

    *Numbers presented are rounded to the nearest whole cent and percentage

    Reorganization Charges. We have excluded the effect of reorganization charges in calculating our non-GAAP measures. In 2024 and 2025 we incurred severance expenses related to the reorganization of the leadership team, which we would not have otherwise incurred in periods presented as part of continuing operations.

    Stock-based Compensation Expense. We have excluded the effect of stock-based compensation expense in calculating our non-GAAP measures. We record non-cash compensation expenses related to grants of options and restricted shares for executives, employees and consultants, and grants of shares to our board of directors. Depending upon the size, timing and the terms of the grants, the non-cash compensation expense may vary significantly but will recur in future periods.

    Litigation Expense. We have excluded the effect of litigation expense in calculating our non-GAAP measures. In the first quarter 2025 we incurred legal fees with respect to a claim filed by the Company alleging patent infringement, which we would not have otherwise incurred in the period presented as part of continuing operations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250507094877/en/

    Investor Contact:

    Louisa Smith

    [email protected]

    Get the next $KRMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KRMD

    DatePrice TargetRatingAnalyst
    2/14/2025$4.50Overweight → Neutral
    Piper Sandler
    7/25/2024$4.00Buy
    B. Riley Securities
    9/7/2023$4.00Buy
    Lake Street
    9/7/2023$4.50Buy
    B. Riley Securities
    11/10/2022$3.00 → $4.00Hold → Buy
    Canaccord Genuity
    11/10/2022$3.00 → $3.50Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $KRMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

      5/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call

      4/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 million, a 23% increase over the prior year period; Full year 2024 net revenues of $33.6 million, an 18% increase over the prior year Fourth quarter 2024 Core business (Domestic and International) net revenues of $8.2 million, a

      3/12/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Tharby Linda M covered exercise/tax liability with 23,587 shares, decreasing direct ownership by 2% to 1,023,163 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      4/23/25 4:12:10 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Wholihan Edward was granted 5,870 shares, increasing direct ownership by 21% to 33,583 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      4/2/25 4:30:38 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Director Matin Shahriar was granted 5,870 shares, increasing direct ownership by 8% to 83,415 units (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      4/2/25 4:30:18 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • KORU Medical Systems downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded KORU Medical Systems from Overweight to Neutral and set a new price target of $4.50

      2/14/25 8:08:51 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities resumed coverage on KORU Medical Systems with a new price target

      B. Riley Securities resumed coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      7/25/24 8:28:49 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on KORU Medical Systems with a new price target

      Lake Street initiated coverage of KORU Medical Systems with a rating of Buy and set a new price target of $4.00

      9/7/23 9:12:10 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Manko Joseph M. Jr. bought $349,999 worth of shares (145,833 units at $2.40) and sold $349,999 worth of shares (145,833 units at $2.40) (SEC Form 4)

      4 - KORU Medical Systems, Inc. (0000704440) (Issuer)

      12/15/23 4:05:24 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Financials

    Live finance-specific insights

    See more
    • KORU Medical Systems Announces Record Q1 2025 Financial Results and Raises 2025 Revenue Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2025. Recent Highlights First quarter 2025 net revenues of $9.6 million, an 18% increase over the prior year period Core business (Domestic and International) net revenues of $9.4 million, a 21% increase over the prior year period Gross profit of $6.0 million, a 19% increase over the prior year period, and gross margin of 62.8%, a 50-basis point improvement over th

      5/7/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems to Report First Quarter 2025 Financial Results on May 7, 2025

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2025 financial results on Wednesday, May 7, 2025. KORU Medical's management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast Details The conference call can be accessed by dialing (877)-407-0784 for participants in the U.S. or Canada and (201)-689-8560 for international call

      4/16/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Announces Fourth Quarter and Full Year 2024 Financial Results With Record Revenues and Gross Profit; Issues Full Year 2025 Guidance

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. The Company also issued guidance for the full year 2025. Recent Highlights Fourth quarter 2024 net revenues of $8.8 million, a 23% increase over the prior year period; Full year 2024 net revenues of $33.6 million, an 18% increase over the prior year Fourth quarter 2024 Core business (Domestic and International) net revenues of $8.2 million, a

      3/12/25 4:05:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/14/24 7:00:30 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by KORU Medical Systems Inc.

      SC 13G/A - KORU Medical Systems, Inc. (0000704440) (Subject)

      11/13/24 4:23:54 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by KORU Medical Systems Inc.

      SC 13G - KORU Medical Systems, Inc. (0000704440) (Subject)

      5/23/24 7:00:28 AM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    SEC Filings

    See more
    • SEC Form 10-Q filed by KORU Medical Systems Inc.

      10-Q - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:22:04 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      5/7/25 4:21:14 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

      8-K - KORU Medical Systems, Inc. (0000704440) (Filer)

      4/7/25 4:06:32 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care

    $KRMD
    Leadership Updates

    Live Leadership Updates

    See more
    • KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023. Ken brings over 30 years of extensive expertise and experience in leading high-performing teams in commercialization and marketing strategy, international expansion, and driving sustainable growth and profitability. As Chief Commercial Officer, Ken will have oversight of the global commercial functio

      11/8/23 4:08:00 PM ET
      $BDX
      $KRMD
      Medical/Dental Instruments
      Health Care
    • KORU Medical Systems, Inc. Announces Appointment of Edward Wholihan to Its Board of Directors

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

      10/4/23 4:05:00 PM ET
      $KRMD
      $MCK
      Medical/Dental Instruments
      Health Care
      Other Pharmaceuticals
    • KORU Medical Systems, Inc. Announces Preliminary Second Quarter 2023 Revenues and Provides Business, Outlook and Executive Updates

      KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced preliminary unaudited revenues for the second quarter 2023 and provided business, outlook and executive updates. The Company reported total net revenues for the second quarter 2023 of approximately $6.9 million, representing growth of approximately 6% compared to the prior year period. Domestic Core revenues increased approximately 8%, International Core revenues increased approximatel

      8/2/23 5:15:00 PM ET
      $KRMD
      Medical/Dental Instruments
      Health Care